Apollo Hospitals (APOLLOHOSP) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
9 Jul, 2026Executive summary
Q2 FY26 consolidated revenue grew 13% year-over-year to INR 6,304 crore (₹63,035 million), with EBITDA up 15% and PAT up 26%.
All core divisions—Healthcare Services, Apollo HealthCo/Digital Health & Pharmacy Distribution, and AHLL/Diagnostics & Retail Health—delivered double-digit revenue growth despite seasonal impacts.
H1 FY26 consolidated revenue was INR 12,146 crore (₹121,456 million), up 14% year-over-year, with EBITDA up 20% and PAT up 33%.
Expansion projects include commissioning six new hospitals by end of next fiscal and adding 4,400 capacity beds (~3,600 census beds) over five years.
Clinical milestones include over 51 lakh surgeries, 27,000 organ transplants, and pioneering robotic telesurgery.
Financial highlights
Q2 FY26 consolidated revenue: INR 6,304 crore (₹63,035 million, +13% YoY); EBITDA: INR 941 crore (₹9,412 million, +15% YoY); PAT: INR 477 crore (₹4,772 million, +26% YoY).
H1 FY26 consolidated revenue: INR 12,146 crore (₹121,456 million, +14% YoY); EBITDA: INR 1,793 crore (₹17,931 million, +20% YoY); PAT: INR 910 crore (₹9,100 million, +33% YoY).
Healthcare Services Q2 revenue: INR 3,169 crore (₹31,690 million, +9% YoY); EBITDA margin: 24.6%.
Apollo HealthCo/Digital Health & Pharmacy Distribution Q2 revenue: INR 2,661 crore (₹26,606 million, +17% YoY); EBITDA: INR 110 crore; GMV at INR 723 crore (+16% YoY); 44 million users.
AHLL/Diagnostics & Retail Health Q2 revenue: INR 474 crore (₹4,739 million, +17% YoY); EBITDA: INR 50 crore (21% YoY); margin at 10.6%.
Outlook and guidance
Organic growth in healthcare services expected to return to 13% in existing beds, with an additional 5% from new beds over the next two years.
Six new hospitals to be fully operational by end of next fiscal, with ramp-up plans staggered across Q3, Q4, and Q1.
Targeting annualized revenue run rate of ₹250 billion by Q4FY27 with 7% EBITDA margin.
Digital business cost structure has stabilized, with further synergies expected post-integration.
Management plans to deepen technology partnerships and expand AI capabilities.
Latest events from Apollo Hospitals
- Q3 FY26 saw 17% revenue and 35% PAT growth, robust expansion, and a Rs.10 interim dividend.APOLLOHOSP
Q3 25/269 Jul 2026 - Q2 FY25 delivered 15% revenue, 30% EBITDA, and 63% PAT growth, with major expansion underway.APOLLOHOSP
Q2 24/258 Jul 2026 - 15% revenue growth, 33% EBITDA rise, and 83% PAT surge, with major digital and pharmacy expansion.APOLLOHOSP
Q1 24/258 Jul 2026 - FY25 revenue up 14% YoY, PAT up 61%, with major expansion and INR 19/share dividend.APOLLOHOSP
Q4 24/2518 Jun 2026 - FY26 revenue up 16%, EBITDA up 25%, PAT up 34%, with major digital and hospital expansion.APOLLOHOSP
Q4 25/2622 May 2026 - Q3 FY25 delivered 14% revenue and 52% PAT growth, with digital and specialty gains.APOLLOHOSP
Q3 24/258 Jan 2026 - Q1 FY26 saw 15% revenue, 26% EBITDA, and 42% PAT growth, with strong digital momentum.APOLLOHOSP
Q1 25/2623 Nov 2025 - Equity infusion and merger set to create India's top integrated pharmacy and digital health platform.APOLLOHOSP
Transaction Rationale, Valuation and Governance Presentation16 Jun 2025 - Strong growth, innovation, and ESG focus reinforce Apollo's leadership in Indian healthcare.APOLLOHOSP
Investor Presentation13 Jun 2025